JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Strona główna・Stock List・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Closed

SectorHealthcare

Buy Sell

Overview

Share price change

24h

Current

Min

Max

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-0.05% downside

News Sentiment

By Acuity

50%

141 / 348 Ranking in Healthcare

Mirati Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Major Central Bank -2-

24 kwi 2026, 19:19 UTC

Acquisitions, Mergers, Takeovers

Intertek Group Rejects EQT's Revised Offer

26 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26 kwi 2026, 23:44 UTC

Earnings

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26 kwi 2026, 23:44 UTC

Earnings

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Gold Falls Amid Dollar's Strength -- Market Talk

26 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24 kwi 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Scoring the Cook Era -- Barrons.com

24 kwi 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

24 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:09 UTC

Earnings

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 kwi 2026, 19:48 UTC

Market Talk

Major News Events

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 kwi 2026, 19:22 UTC

Earnings

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 kwi 2026, 19:06 UTC

Earnings

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 kwi 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 kwi 2026, 18:30 UTC

Acquisitions, Mergers, Takeovers

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 kwi 2026, 18:28 UTC

Acquisitions, Mergers, Takeovers

Intertek Rejects Revised EQT Offer

24 kwi 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 kwi 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 kwi 2026, 17:42 UTC

Earnings

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 kwi 2026, 17:28 UTC

Earnings

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Peer Comparison

Price change

Mirati Therapeutics Inc Forecast

Price Target

By TipRanks

-0.05% downside

12 Months Forecast

Average 58.67 USD -0.05%

High 59 USD

Low 58 USD

Based on 5 Wall Street analysts offering 12 month price targets forMirati Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Mirati Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

141 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.